Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes (REGENT-1-US)

  • End date
    Sep 2, 2023
  • participants needed
  • sponsor
    DyaMX Inc.
Updated on 2 May 2022
hemoglobin a1c


This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.


Individuals who sign the informed consent will be screened for study eligibility. Eligible participants will be treated with the Endogenex procedure and followed up for 48 weeks.

Condition Diabetes, Diabetes Type 2, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Diabetes Mellitus
Treatment The Endogenex Device
Clinical Study IdentifierNCT05014204
SponsorDyaMX Inc.
Last Modified on2 May 2022


Yes No Not Sure

Inclusion Criteria

22- 65 years of age
Current diagnosis of T2D
History of T2D for at least 3 years and less than or equal to 10 years
HbA1C of 7.5-10.0%, inclusive
BMI 24-40 kg/m2, inclusive
On two to three non-insulin glucose lowering mediations, with one at maximum tolerated dose and another at half-maximum dose at least, with no changes in medication for at least 12 weeks prior to baseline visit prior to baseline visit
History of failed attempt to reach glycemic goal by lifestyle modifications
Weight stability (defined as a < 5% change in body weight) for at least 12 weeks prior to the screening visit
Agree not to donate blood during participation in the study
Able to comply with study requirements and understand and sign the Informed Consent Form
Women of childbearing potential must be using an acceptable method of contraception throughout the study
Willing and able to use CGM for the duration of the study and comply with study visits and study tasks as required per protocol
Proof of COVID 19 vaccination

Exclusion Criteria

Diagnosed with type 1 diabetes
History of diabetic ketoacidosis or hyperosmolar nonketotic coma
Probable insulin production failure, defined as overnight fasting C-peptide serum <1 ng/mL (333pmol/l)
Previous use of any types of insulin for >1 month (at any time, except for treatment of gestational diabetes) in last 2 years
Current use of insulin
Hypoglycemia unawareness
History of ≥1 severe hypoglycemia episode (defined by needing for third-party assistance) in past 6 months from the screening visit
Known autoimmune disease, as evidenced by a positive anti-glutamic acid decarboxylase (GAD) test, including but not limited to celiac disease, or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder. (Participants with adequately controlled primary hypothyroidism may be included)
Previous GI surgery that has changed GI anatomy or could limit treatment of the duodenum, such as Billroth 2, Roux-en-Y gastric bypass, gastric band or other similar procedures or conditions
Known history of a structural or functional disorder of the upper GI tract that may impede passage of the device through the upper GI tract or increase risk of tissue damage during an endoscopic procedure, including esophagitis, stricture/stenosis, varices, diverticula, or other disorder of the esophagus, stomach and duodenum
Active H. pylori infection (Participants with active H. pylori may continue with the screening process if they are treated with an appropriate antibiotic regimen)
History of, or gastrointestinal symptoms suggestive of gastroparesis
Acute gastrointestinal illness in the previous 7 days
Known history of irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease and Celiac disease
History of chronic or acute pancreatitis
Known active hepatitis or active liver disease other than NASH/NAFLD
Alcoholic liver disease, as indicated by ANI > 0
Current use of anticoagulation therapy (such as warfarin) that cannot be discontinued for 7 days before and 14 days after the procedure
Current use of P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be discontinued for 14 days before and 14 days after the procedure
Unable to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during treatment through 4 weeks following the procedure. Use of acetaminophen and low dose aspirin is allowed
Use of systemic glucocorticoids (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 12 weeks prior to the baseline visit
Use of drugs known to affect GI motility (e.g. Metoclopramide)
Use of weight loss medications such as Meridia, Xenical, Phentermine or over-the-counter weight loss medications (prescription medication)
Currently taking, or unable to stop taking dietary supplements or herbal agents, including vitamin C or multivitamins containing vitamin C at >500 mg per day, multivitamins containing biotin (vitamin B7), and supplements for hair, skin, and nail growth. Multivitamins not containing biotin are permitted
Persistent anemia, defined as hemoglobin <10 g/dL
Known history of hemoglobinopathy
Known history of blood donation or transfusion within 3 months prior to the Screening Visit
Known history of cardiac arrythmia
Significant cardiovascular disease, including known history of valvular disease, or myocardial infarction, heart failure, transient ischemic attack, or stroke within 6 months prior to the Screening Visit
Estimated glomerular filtration rate (eGFR) ≤ 60 ml/min/1.73m2 (estimated by MDRD)
Known immunocompromised status, including but not limited to individuals who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months, who have clinically significant leukopenia, who are positive for the human immunodeficiency virus (HIV) or whose immune status makes the participant a poor candidate for clinical trial participation in the opinion of the investigator
History of secondary hypothyroidism or inadequately controlled primary hypothyroidism (TSH value outside the normal range at screening)
With any implanted electronic devices or duodenal metallic implants
Not a candidate for upper GI endoscopy or general anesthesia
Active illicit substance abuse or alcoholism (>2 drinks/day regularly)
Active malignancy within the last 5 years (excluding non-melanoma skin cancers)
Women breastfeeding
Participating in another ongoing clinical trial of an investigational drug or device
Any other mental or physical condition which, in the opinion of the study investigator, makes the participant a poor candidate for clinical trial participation
Critically ill or has a life expectancy <3 years
Additional exclusion criteria to be confirmed during the screening process
HbA1c < 7.5% or > 10% at baseline visit
Any severe hypoglycemic event since the screening visit
CGM readings <54 mg/dl in more than 1% of time by CGM since the screening visit
CGM readings > 360 mg/dL in more than 1% of time
Mean of 3 separate blood pressure measurements >180 mmHg (systolic) or >100 mmHg (diastolic)
Women of child-bearing potential with a positive urine pregnancy test at baseline visit
LA Grade C or greater esophagitis on endoscopy
Abnormalities of the GI tract preventing endoscopic access to the duodenum
Anatomic abnormalities in the duodenum that would preclude the completion of the treatment procedure, including tortuous anatomy
Endoscopic observation of upper gastrointestinal abnormality such as ulcers, polyps, varices, strictures, congenital or intestinal telangiectasia
Any other anatomical or endoscopic abnormalities/characteristics that, in the opinion of the investigator, would preclude safe use of the investigational device or procedure
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note